Vetter Pharma-Fertigung GmbH & Co. KG — Cyborg Score 7/10
Strong
Contract Development and Manufacturing Organization (CDMO) services for aseptic fill-and-finish injectable drugs
Strategic Profile
Over 80% of the company's active projects are biologics, positioning Vetter as a specialized partner in the high-growth biologics sector. Founded in Ravensburg in 1950 and remaining family-owned, the company has built decades of manufacturing expertise and regulatory credibility. With production facilities in Germany, Austria, and the US, and sales locations across Asia-Pacific markets including Japan, China, South Korea and Singapore, Vetter operates a globally diversified footprint serving multinational pharma and biotech clients.
Cyborg Score Rationale
Vetter is a well-capitalized, privately held CDMO with €1.114 billion in revenue (2024), significant operational scale (6,590 employees), and deep expertise in aseptic manufacturing for high-margin biologics. Strong competitive positioning in a consolidating CDMO market, though as a private company lacks the scale and M&A optionality of larger public peers. Family ownership provides stability but may limit growth capital and strategic agility.
Top Insights
Revenue of €1.114 billion in 2024 with 6,590 employees reflects strong operational scale and capital intensity of aseptic manufacturing, supporting pricing power and recurring revenue from long-term pharma partnerships.
Over 80% of active projects are biologics, indicating deep exposure to highest-margin injectable drugs; aligns Vetter's growth with accelerating biotech outsourcing and GLP-1 agonist demand.
Acquisition of clinical manufacturing site in Rankweil, Austria and investments in cleanrooms, visual inspection automation and production capacity signal continued capital deployment to expand early-phase and commercial manufacturing footprint and maintain regulatory leadership.
Named Competitors
Catalent — Global CDMO offering fill-finish, drug substance, and drug product services
Lonza — Swiss CDMO with integrated pharma and biotech manufacturing capabilities
Recro Pharma — Specialist CDMO focused on sterile fill-finish and injectable manufacturing
Recent Developments
(2024) Revenue reached €1.114 billion with 6,590 employees
(Recent) Acquisition and integration of clinical manufacturing site in Rankweil, Austria to expand early clinical capacity
(Recent) Investments in new headquarters in Ravensburg and cleanroom automation technology
Open the full interactive Vetter Pharma-Fertigung GmbH & Co. KG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.